Bioactive Effect of Plasma-Rich in Growth Factors (PRGFs) on Cell-Based In Vitro Models of Skin Inflammation in Relation to Inflammatory Skin Disorders

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Dec 23

PMID 39712761

Authors

Eduardo Anitua

Roberto Tierno

Zurine Martinez de Lagran

Mohammad H Alkhraisat

Affiliations

Soon will be listed here.

Abstract

Plasma rich in growth factors (PRGFs) has proven potentially beneficial as a bioregenerator in patients with chronic skin disorders due to its anti-inflammatory effect. However, its therapeutic potential may be limited by soluble autoimmune components associated with inflammatory dermatoses in blood plasma. To evaluate the impact of skin health status on cell bioactivity, PRGF was prepared from healthy (H) donors as well as from individuals with atopic dermatitis (AD), psoriasis (PS), or lichen sclerosus (LS). Leukocyte exclusion and heat inactivation (Immunosafe treatment) were evaluated as potential methods to reduce the inflammatory components of the samples under study. The biological effect of PRGF-derived formulations was investigated using cell-based in vitro skin inflammation models, including human dermal fibroblasts (HDFs) and human epidermal keratinocytes (HEKs) exposed to a pro-inflammatory environment. The data confirmed that viability, proliferation, and migration rates were enhanced in inflamed cell cultures supplemented with PRGF formulations compared to those maintained in standard culture media. Nevertheless, significant differences have been identified. About the healthy control, inflamed epidermal keratinocytes supplemented with most PRGF-based formulations obtained from pathological donors (PS/LS) showed lower viability. Heat inactivation significantly promoted cell proliferation in epidermal keratinocytes supplemented with SP (PS/LS) and L-PRP supernatant (LSP) samples (AD), and also cell migration in inflamed HDF (AD/H/LS) and HEK (AD/LS) models supplemented with LSP. Leukocyte exclusion improved cell behavior in terms of migration with the only exception of LSP from individuals with AD added to inflamed HEK cultures. In conclusion, PRGF derived from pathological patients contains autoimmune components that could compromise its effectiveness as a therapy for treating individuals with chronic inflammatory disorders. However, heat inactivation (Immunosafe treatment) or leukocyte exclusion could minimize local adverse effects.

References

Casabona F, Gasparini G, Cozzani E, Barbazza A, Casabona F, Carmisciano L . Improvement in quality of life and sexual function in patients affected by vulvar lichen sclerosus treated with combined autologous platelet-rich plasma and fat grafting. Eur J Dermatol. 2023; 33(3):249-254. DOI: 10.1684/ejd.2023.4480. View

Anitua E . Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999; 14(4):529-35. View

Kauhl W, Pototschnig H, Paasch U . Can Platelet-Rich Plasma Reduce the Burden of Inflammatory Skin Diseases Such as Psoriasis and Atopic Dermatitis?. Cureus. 2021; 13(10):e18472. PMC: 8565102. DOI: 10.7759/cureus.18472. View

Anitua E, Tierno R, Martinez de Lagran Z, Alkhraisat M . Impact of inflammatory skin conditions on the biological profile of plasma rich in growth factor. Tissue Cell. 2024; 91:102560. DOI: 10.1016/j.tice.2024.102560. View

Casabona F, Gambelli I, Casabona F, Santi P, Santori G, Baldelli I . Autologous platelet-rich plasma (PRP) in chronic penile lichen sclerosus: the impact on tissue repair and patient quality of life. Int Urol Nephrol. 2017; 49(4):573-580. DOI: 10.1007/s11255-017-1523-0. View

Goldstein A, King M, Runels C, Gloth M, Pfau R . Intradermal injection of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol. 2016; 76(1):158-160. DOI: 10.1016/j.jaad.2016.07.037. View

Delgado D, Bilbao A, Beitia M, Garate A, Sanchez P, Gonzalez-Burguera I . Effects of Platelet-Rich Plasma on Cellular Populations of the Central Nervous System: The Influence of Donor Age. Int J Mol Sci. 2021; 22(4). PMC: 7915891. DOI: 10.3390/ijms22041725. View

Franic D, Iternicka Z, Franic-Ivanisevic M . Platelet-rich plasma (PRP) for the treatment of vulvar lichen sclerosus in a premenopausal woman: A case report. Case Rep Womens Health. 2018; 18:e00062. PMC: 5960026. DOI: 10.1016/j.crwh.2018.e00062. View

Peterson D, Damsky W, Vesely M . Treatment of lichen sclerosus and hypertrophic scars with dupilumab. JAAD Case Rep. 2022; 23:76-78. PMC: 9014314. DOI: 10.1016/j.jdcr.2022.03.002. View

10.

Zaki S, Mardyansyah , Oktarina C, Purwoko R, Sutanto H . Platelet-Rich Plasma for the Treatment of Atopic Dermatitis: A Literature Review. J Clin Aesthet Dermatol. 2024; 17(7):43-49. PMC: 11238712. View

11.

Chakravdhanula U, Anbarasu K, Verma V, Beevi S . Clinical efficacy of platelet rich plasma in combination with methotrexate in chronic plaque psoriatic patients. Dermatol Ther. 2016; 29(6):446-450. DOI: 10.1111/dth.12388. View

12.

Bunjaj A, Brandao L, Siracuse K, Soti V . Platelet-Rich Plasma for the Treatment of Plaque Psoriasis: A Systematic Review. Cureus. 2023; 15(12):e50356. PMC: 10713448. DOI: 10.7759/cureus.50356. View

13.

Paganelli A, Contu L, Condorelli A, Ficarelli E, Motolese A, Paganelli R . Platelet-Rich Plasma (PRP) and Adipose-Derived Stem Cell (ADSC) Therapy in the Treatment of Genital Lichen Sclerosus: A Comprehensive Review. Int J Mol Sci. 2023; 24(22). PMC: 10671587. DOI: 10.3390/ijms242216107. View

14.

Iannone L, Bennardo L, Palleria C, Roberti R, De Sarro C, Naturale M . Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS One. 2020; 15(11):e0241575. PMC: 7608898. DOI: 10.1371/journal.pone.0241575. View

15.

Borsky P, Chmelarova M, Fiala Z, Hamakova K, Palicka V, Krejsek J . Aging in psoriasis vulgaris: female patients are epigenetically older than healthy controls. Immun Ageing. 2021; 18(1):10. PMC: 7927262. DOI: 10.1186/s12979-021-00220-5. View

16.

Huber S, Montalvao S, Sachetto Z, Santos Duarte Lana J, Annichino-Bizzacchi J . Characterization of autologous platelet rich plasma (PRP) and its biological effects in patients with Behçet's Disease. Regen Ther. 2021; 18:339-346. PMC: 8441104. DOI: 10.1016/j.reth.2021.08.010. View

17.

Mochizuki T, Ushiki T, Suzuki K, Sato M, Ishiguro H, Suwabe T . Characterization of Leukocyte- and Platelet-Rich Plasma Derived from Female Collage Athletes: A Cross-Sectional Cohort Study Focusing on Growth Factor, Inflammatory Cytokines, and Anti-Inflammatory Cytokine Levels. Int J Mol Sci. 2023; 24(17). PMC: 10488049. DOI: 10.3390/ijms241713592. View

18.

Goldstein A, Mitchell L, Govind V, Heller D . A randomized double-blind placebo-controlled trial of autologous platelet-rich plasma intradermal injections for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol. 2019; 80(6):1788-1789. DOI: 10.1016/j.jaad.2018.12.060. View

19.

Alves R, Grimalt R . A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification. Skin Appendage Disord. 2018; 4(1):18-24. PMC: 5806188. DOI: 10.1159/000477353. View

20.

Thyssen J, Halling A, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg J . Comorbidities of atopic dermatitis-what does the evidence say?. J Allergy Clin Immunol. 2023; 151(5):1155-1162. DOI: 10.1016/j.jaci.2022.12.002. View